Pharsight

Mirena patents expiration

MIRENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

Mirena is owned by Bayer Hlthcare.

Mirena contains Levonorgestrel.

Mirena has a total of 4 drug patents out of which 0 drug patents have expired.

Mirena was authorised for market use on 06 December, 2000.

Mirena is available in intrauterine device;intrauterine dosage forms.

Mirena can be used as a method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus, a method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system.

The generics of Mirena are possible to be released after 01 April, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Aug 20, 2023

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

MIRENA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic